Risk of Inflammation, Retinal Vasculitis, and Retinal Occlusion-Related Events with Brolucizumab: Post Hoc Review of HAWK and HARRIER

An independent Safety Review Committee (SRC), supported by Novartis Pharma AG, analyzed investigator-reported cases of intraocular inflammation (IOI), endophthalmitis, and retinal arterial occlusion in the phase 3 HAWK and HARRIER trials of brolucizumab versus aflibercept in neovascular age-related...

Celý popis

Podrobná bibliografia

Vydané v:	Ophthalmology (Rochester, Minn.) Ročník 128; číslo 7; s. 1050
Hlavní autori:	Monés, Jordi, Srivastava, Sunil K, Jaffe, Glenn J, Tadayoni, Ramin, Albini, Thomas A, Kaiser, Peter K, Holz, Frank G, Korobelnik, Jean-Francois, Kim, Ivana K, Pruente, Christian, Murray, Timothy G, Heier, Jeffrey S
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 01.07.2021
Predmet:	neovascular age-related macular degeneration intraocular inflammation safety brolucizumab retinal vasculitis retinal arterial occlusion retinal occlusive vasculitis retinal vascular occlusion
ISSN:	1549-4713, 1549-4713
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!